{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:08:10Z","timestamp":1784639290457,"version":"3.55.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:p>Deucravacitinib may confer an additive effect in some patients with psoriasis and psoriatic arthritis whose disease is not adequately controlled on systemic monotherapy. This study found that deucravacitinib proved to be a safe adjunctive therapy to patients with refractory disease.<\/jats:p>","DOI":"10.1093\/bjd\/ljad473","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T23:17:17Z","timestamp":1701127037000},"page":"451-453","source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0161-5723","authenticated-orcid":false,"given":"Sophie","family":"Gu\u00e9nin","sequence":"first","affiliation":[{"name":"The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Andrews","sequence":"additional","affiliation":[{"name":"The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00a0G","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"2024021708484703200_ljad473-B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024021708484703200_ljad473-B2","doi-asserted-by":"crossref","first-page":"2154122","DOI":"10.1080\/09546634.2022.2154122","article-title":"Deucravacitinib in the treatment of psoriasis","volume":"34","author":"Estevinho","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2024021708484703200_ljad473-B3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024021708484703200_ljad473-B4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","article-title":"Deucravacitinib for the treatment of psoriatic disease","volume":"23","author":"L\u00e9","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2024021708484703200_ljad473-B5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad473\/56352970\/ljad473.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/3\/451\/56690265\/ljad473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/3\/451\/56690265\/ljad473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T08:49:38Z","timestamp":1708159778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/3\/451\/7451233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,11,27]]},"published-print":{"date-parts":[[2024,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad473","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,11,27]]}}}